Salarius Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2014 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Salarius Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2014 to Q2 2025.
  • Salarius Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2025 was -$958K, a 32.8% increase year-over-year.
  • Salarius Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2025 was -$5.1M, a 21.1% increase year-over-year.
  • Salarius Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$5.58M, a 55.5% increase from 2023.
  • Salarius Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$12.5M, a 60.3% increase from 2022.
  • Salarius Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$31.6M, a 148% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2025 -$958K +$467K +32.8% Jun 30, 2025 10-Q 2025-08-12
Q1 2025 -$1.71M +$5.76K +0.34% Mar 31, 2025 10-Q 2025-08-12
Q4 2024 -$1.46M -$582K -66% Dec 31, 2024 10-K 2025-03-21
Q3 2024 -$972K +$1.47M +60.2% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$1.42M +$2.45M +63.3% Jun 30, 2024 10-Q 2025-08-12
Q1 2024 -$1.72M +$3.63M +67.9% Mar 31, 2024 10-Q 2025-08-12
Q4 2023 -$882K +$5.49M +86.2% Dec 31, 2023 10-K 2025-03-21
Q3 2023 -$2.44M +$12M +83% Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$3.88M +$841K +17.8% Jun 30, 2023 10-Q 2024-11-14
Q1 2023 -$5.34M +$768K +12.6% Mar 31, 2023 10-Q 2024-11-14
Q4 2022 -$6.37M -$2.27M -55.2% Dec 31, 2022 10-K 2024-03-22
Q3 2022 -$14.4M -$10.7M -286% Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$4.72M -$1.64M -53.5% Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$6.11M -$4.26M -230% Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$4.1M -$2.34M -132% Dec 31, 2021 10-K 2023-03-27
Q3 2021 -$3.74M -$2.02M -118% Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$3.07M -$1.29M -72.3% Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$1.85M +$232K +11.1% Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$1.77M +$115K +6.12% Dec 31, 2020 10-K 2022-03-25
Q3 2020 -$1.72M +$911K +34.7% Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$1.78M -$881K -97.5% Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$2.08M -$562K -36.9% Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$1.88M +$126K +6.27% Dec 31, 2019 10-K 2021-03-18
Q3 2019 -$2.63M -$2.32M -755% Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$904K -$1.01M -912% Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$1.52M -$1.14M -299% Mar 31, 2019 10-Q 2020-11-12
Q4 2018 -$2.01M +$6.02M +75% Dec 31, 2018 10-K 2019-03-06
Q3 2018 -$307K +$9.02M +96.7% Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $111K +$8.92M Jun 30, 2018 10-Q 2019-11-12
Q1 2018 -$382K +$7.89M +95.4% Mar 31, 2018 10-Q 2019-11-12
Q4 2017 -$8.03M -$128K -1.63% Dec 31, 2017 10-K 2019-03-06
Q3 2017 -$9.33M +$1.31M +12.3% Sep 30, 2017 10-K 2019-03-06
Q2 2017 -$8.8M +$2.56M +22.5% Jun 30, 2017 10-K 2019-03-06
Q1 2017 -$8.27M +$1.32M +13.8% Mar 31, 2017 10-K 2019-03-06
Q4 2016 -$7.9M -$7.23K -0.09% Dec 31, 2016 10-K 2018-03-07
Q3 2016 -$10.6M -$2.48M -30.5% Sep 30, 2016 10-K 2018-03-07
Q2 2016 -$11.4M -$4.28M -60.5% Jun 30, 2016 10-K 2018-03-07
Q1 2016 -$9.59M -$3.57M -59.4% Mar 31, 2016 10-K 2018-03-07
Q4 2015 -$7.89M -$4.15M -111% Dec 31, 2015 10-K 2017-03-08
Q3 2015 -$8.15M -$6.17M -310% Sep 30, 2015 10-K 2017-03-08
Q2 2015 -$7.08M -$4.89M -223% Jun 30, 2015 10-K 2017-03-08
Q1 2015 -$6.02M -$5.92M -6390% Mar 31, 2015 10-K 2017-03-08
Q4 2014 -$3.74M Dec 31, 2014 10-K 2016-03-08
Q3 2014 -$1.99M Sep 30, 2014 10-K 2016-03-08
Q2 2014 -$2.19M Jun 30, 2014 10-K 2016-03-08
Q1 2014 -$92.7K Mar 31, 2014 10-K 2016-03-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.